Drug Patents owned by Actelion
1. Drug name - OPSUMIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(3 years from now) | |
| CN100432070C | ACTELION | Novel Sulfonamide Compounds And Their Use As Endothelin Receptor Antagonists |
Dec, 2020
(1 year, 9 months ago) | |
| CN1524079A | ACTELION | Novel Sulfonamide Compounds And Their Use As Endothelin Receptor Antagonists |
Dec, 2020
(1 year, 9 months ago) | |
| EP1345920A1 | ACTELION | Novel Sulfamides And Their Use As Endothelin Receptor Antagonists |
Dec, 2026
(4 years from now) | |
| EP1345920B1 | ACTELION | Novel Sulfamides And Their Use As Endothelin Receptor Antagonists |
Dec, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(3 years from now) | |
| US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(4 years from now) | |
| US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(6 years from now) | |
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(6 years from now) | |
Drugs and Companies using MACITENTAN ingredient
Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition; Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition; Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
2. Drug name - TRACLEER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(3 years from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(5 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 32MG | TABLET, FOR SUSPENSION;ORAL | Prescription |
3. Drug name - UPTRAVI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(4 years from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(7 years from now) | |
| CN1516690A | ACTELION | Heterocyclic Derivative And Medicine |
Apr, 2022
(5 months ago) | |
| CN1301973C | ACTELION | Heterocyclic Derivative And Medicine |
Apr, 2022
(5 months ago) | |
| CN102459198B | ACTELION | Crystal |
Jun, 2030
(7 years from now) | |
| CN102459198A | ACTELION | Crystal |
Jun, 2030
(7 years from now) | |
| EP1400518A4 | ACTELION | Heterocyclic Compound Derivatives And Medicines |
Apr, 2022
(5 months ago) | |
| EP1400518B1 | ACTELION | Heterocyclic Compound Derivatives And Medicines |
Apr, 2022
(5 months ago) | |
| EP1400518A1 | ACTELION | Heterocyclic Compound Derivatives And Medicines |
Apr, 2022
(5 months ago) | |
| EP2447254A4 | ACTELION | Crystals |
Jun, 2030
(7 years from now) | |
| EP2447254A1 | ACTELION | Crystals |
Jun, 2030
(7 years from now) | |
| EP3275871A1 | ACTELION | Crystals |
Jun, 2030
(7 years from now) | |
| EP2447254B1 | ACTELION | Crystals |
Jun, 2030
(7 years from now) | |
| EP3275871B1 | ACTELION | Crystals |
Jun, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(6 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(7 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(14 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(14 years from now) | |
Drugs and Companies using SELEXIPAG ingredient
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 1.8MG/VIAL | POWDER;INTRAVENOUS | Prescription |
4. Drug name - VELETRI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598227 | ACTELION | Epoprostenol formulation and method of making thereof |
Feb, 2027
(4 years from now) | |
| US8318802 | ACTELION | Epoprostenol formulation and method of making thereof |
Mar, 2027
(4 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5MG BASE/VIAL | INJECTABLE;INJECTION | Prescription |
| EQ 1.5MG BASE/VIAL | INJECTABLE;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.